Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lupus

Treatment offers new hope for lupus – and maybe for other autoimmune diseases too

When real patients have unprecedented positive outcomes to a new treatment, it’s tempting to talk about it as “breakthrough” for medical science. This describes the excitement around a new report from researchers in Germany of a radical new treatment for lupus.

The Conversation

Breakthrough gives hope to autoimmune disease sufferers

Possible treatment for rheumatoid arthritis and multiple sclerosis

Wales Online

Scientists hail autoimmune disease therapy breakthrough

Study finds CAR T-cell treatment sends lupus into remission, raising hopes it could be used to treat diseases such as multiple sclerosis

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Disability advocates call for better support for people in rural, regional and remote NSW

Pauline Follett, who lives with cerebral lupus, has had two National Disability Insurance Scheme applications rejected within three years. According to a Disability Advocacy NSW report, people in remote areas of NSW face challenges in providing the evidence required.

ABC News

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Benzinga

What is lupus? New treatment could end the need for lifelong medication

Three patients have undergone CAR T-cell therapy, which genetically alters their immune system to protect their organs

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread

Aurinia Pharmaceuticals hired a trio of executives in a move that suggests it's nowhere near a buyout — and AUPH stock plummeted Friday.

Investors Business Daily

Post-Roe, many autoimmune patients lose access to 'gold standard' drug

Six days after the Supreme Court struck down the right to abortion, lupus patient Becky Schwarz got an unexpected message from her rheumatologist.

Los Angeles Times

Why Is Kezar Life Sciences Surging By 78%? 25 Stocks Moving In Tuesday's Pre-Market Session

Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

Benzinga

Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

Benzinga

Programme held to create awareness on lupus

MYSURU

The Hindu

Lupus: Five things to know about autoimmune disease triggers

From stress to sunlight to hormones, here are five common factors that can contribute to a flare-up of Lupus symptoms.

Al Jazeera

World Lupus Day marked with events and focus on mental health

A UK CHAIRTY is urging the public to join efforts to raise awareness of an incurable autoimmune disease as World Lupus Day is marked.

The National (Scotland)

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Wells Fargo Analyst Has Questions On Kezar's Lupus Nephritis Data Readout, Stock Plunges

Wells Fargo is reiterating its Overweight rating after Kezar Life Sciences Inc's (NASDAQ:KZR) zeto (KZR-616) Phase 2 trial in dermatomyositis/polymyositis failed to top placebo on the trial's primary endpoint of mean total improvement score (TIS). The analysts had viewed the program as a free call option for shares at these levels and argued that there…

The Independent UK

Scientists find genetic cause for autoimmune disease lupus

Lupus is a long-term condition that causes joint pain and skin rashes and has no cure.

The Guardian - UK

A moment that changed me: my dream job healed my excruciating pain

The autoimmune disease lupus had ruined my life until I landed an interview at the Southbank Centre. After years of trying to fit in I’d found my tribe – and a way to get better

Creative Bloq

12 of the best JavaScript examples

Get inspiration from innovative, interesting examples of JavaScript in action.

Get all your
news in one place.

100’s of premium titles.
One news app.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

European Medicines Agency

75 stories

Amgen Inc

70 stories

US Food and Drug Administration

58 stories

Soundcloud

50 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.